Ion Channels in Drug Discovery

Anna Johansson BioSeeker Group Anna.Johansson at
Mon Jun 3 17:10:07 EST 2002


1. New Report: - Ion Channel Assays in the Drug Discovery Process -
2. New ion channels may be the next target for anti-inflammatory and analgesic drugs
3. Other Reports by BioSeeker Group
4. Conference opportunity


(Read more about this report on

BioSeeker Group AB have recognized the interest and need for a comprehensive
study within the field of ion channel assay technology. We have identified 23 companies with a strong focus within this field. "Ion Channel Assays in the Drug Discovery Process" is produced to compiles and assesses the available and future possibilities in ion channel assays. It provides you with an outlook at the competitive landscape of companies in this field, and guides the user to
technologies that suite different segments of the drug discovery process.

Ion channels play an important role in numerous cell types and occur as large families of related genes with cell-specific expression patterns.
Considering the publication of the human genome and the progress in transcription profiling revealing the tissue specific distributions of ion channels, they will play a much more important role as therapeutic drug targets in the future. Combined with cell-based assays providing
biologically relevant information to genomic and proteomic information, ion channels will be a favorable class of selective, tissue specific, drug targets. With the demand for screening large compound collections against an
increasing number of therapeutic targets, there has been a stimulated requirement of developing automation, miniaturization and high throughput assay systems. The shrinking assay volume requires the development of homogenous assay formats and higher detection sensitivity. The technology employed for ion channel screening includes, binding assays, fluorometric imaging and voltage sensing.

Companies included in the report: Abbott laboratories, ALA Instruments, Aurora Biomed Inc, Aurora Biosciences, AVIVA Biosciences, Axon Instruments, BioFocus/Cambridge Drug Discovery, Calipher Technologies, Cambridge Drug Discovery Holdings Ltd., CeNeS, Cellectricon AB, Cytion, Cytocentrics (CCS) GmbH, Cytoplex, Essen Instruments, EVOTEC/Genion, IonGate Biosciences, Molecular Devices Corp, Nanion Technologies, Packard Bioscience, Scion Pharmaceuticals Inc., Sophion Bioscience A/S.

For more information please contact us at BioInfo at

Order fax: +46-8-56849191
Order phone: +46-8-56849192


Novartis Research Foundation and The Scripps Research Institute (TSRI) have published a research article with the title "A novel heat-sensitive TRP channel expressed in keratinocytes". The channel was shown to be a temperature-sensing channel activated at temperatures above 33° C (91.5° F) allowing ions to cross the cell membrane. This discovery will open opportunities for novel targets for antiinflammatory and analgetic drugs. Published online May 16, 2002; 10.1126/science.1073140 (Science Express Reports).
CeNeS Pharmaceuticals has announced postive interim results from a Phase II trials of CNS 5161 for neuropathic pain. CNS 5161 is a blocker of the N-methyl-D-aspartate (NMDA) ion channel associated with the glutamate receptor. 
Agensys has announced the issuance of U.S. patents on two targets for cancer therapy and diagnosis. One is STEAP-1, that is a cell surface ion channel, expressed at high levels in all prostate cancer cells, also expressed in other solid tumors including bladder, lung and colon.


* Commercializing on Tumor Antigens - Analytical Perspectives

* Emerging Cancer Therapeutics

* Cancer Immunotherapy Beyond Monoclonals

* Year 2001 Achievements in Cancer Vaccine R&D

* Swedish Biotechnology Industry

* Anti-fungal R&D
* Dermatitis therapy R&D
* Dossiers for feeding pharmaceutical pipelines
* Pan European Investors in Biotechnology
* Swedish Investors in Biotechnology

* Company profiles

BioSeeker Group AB
Björnnäsvägen 21
BioInfo at


BioNetwork 2002 is the premier  bio-partnering event for biotech and pharma business development and licensing executives worldwide. With a unique structure of industry case studies, roundtable discussion groups and one-to-one meetings, attendees will hear the partnering strategies of big pharma throug  to mid-sized biotechs and enjoy over 17 hours of both formal and informal networking.  So, to meet 200 senior business development and licensing professionals from over 15 countries and hear from  industry leaders such as: Immunex, Millenium, Novartis, Johnson & Johnson, Schering, CAT, Vertex and Oxford Glycoscienes, book your place now!

For more information, please visit or contact Jonathan Ballantine (jonathan5 at
BioSeeker Group is a European based business and competitive intelligence company in the field of biotechnology and pharmaceutical industry. We have since early 1999 provided decision-makers, investors, and management people with candid, credible research and analysis coverage on biotechnology and pharmaceutical companies.

This electronic letter has been sent to you personally in the belief that it would be of interest to you. If you feel this message has been sent to you inerror please reply with remove to unsubscribe at


More information about the Cellbiol mailing list